Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

121. Implant Based Breast Reconstruction With Acellular Dermal Matrix: Safety Data From an Open-label, Multicenter, Randomized, Controlled Trial in the Setting of Breast Cancer Treatment

Implant Based Breast Reconstruction With Acellular Dermal Matrix: Safety Data From an Open-label, Multicenter, Randomized, Controlled Trial in the Setting of Breast Cancer Treatment 30308615 2018 10 19 1528-1140 2018 Oct 17 Annals of surgery Ann. Surg. Implant Based Breast Reconstruction With Acellular Dermal Matrix: Safety Data From an Open-label, Multicenter, Randomized, Controlled Trial in the Setting of Breast Cancer Treatment. 10.1097/SLA.0000000000003054 To evaluate clinical outcomes (...) of using acellular dermal matrix (ADM) with implant based breast reconstructions (IBBRs) in a randomized controlled trial. The use of ADMs in IBBRs is widespread, but link between ADM and complications remain a controversial topic. In view of reports concerning harm, we present 6-months safety data of ADM-assisted IBBR in the setting of breast cancer treatment. An open-label, randomized, controlled trial recruiting patients from 4 centers in Sweden and 1 in UK. Eligible were women with breast cancer

EvidenceUpdates2018

122. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy

A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy 30237023 2018 11 17 1873-7560 74 6 2018 Dec European urology Eur. Urol. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial (...) Biopsy. 731-738 S0302-2838(18)30604-3 10.1016/j.eururo.2018.08.019 Discriminating indolent from clinically significant prostate cancer (PCa) in the initial biopsy setting remains an important issue. Prospectively evaluated diagnostic assays are necessary to ensure efficacy and clinical adoption. Performance and utility assessment of ExoDx Prostate (IntelliScore) (EPI) urine exosome gene expression assay versus standard clinical parameters for discriminating Grade Group (GG) ≥2 PCa from GG1 PCa

EvidenceUpdates2018

123. Population health interventions to improve colorectal cancer screening by fecal immunochemical tests: A systematic review

Population health interventions to improve colorectal cancer screening by fecal immunochemical tests: A systematic review 30367972 2018 11 16 1096-0260 118 2018 Oct 24 Preventive medicine Prev Med Population health interventions to improve colorectal cancer screening by fecal immunochemical tests: A systematic review. 113-121 S0091-7435(18)30340-2 10.1016/j.ypmed.2018.10.021 Despite clear evidence that colorectal cancer (CRC) screening reduces mortality, screening, including fecal (...) preventative services, and provider alerts) have the potential to significantly increase screening participation. However, such programs must also follow-up patients with abnormal FIT results. Copyright © 2018 Elsevier Inc. All rights reserved. Issaka Rachel B RB Clinical Research & Public Health Sciences Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America; Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA, United

EvidenceUpdates2018

124. OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients

OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients 30333540 2018 10 18 1572-0241 2018 Oct 17 The American journal of gastroenterology Am. J. Gastroenterol. OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients. 10.1038/s41395-018-0353-8 Gastritis OLGA-staging ranks the risk for gastric cancer (GC) in progressive stages (0-IV). This long-term follow-up study quantifies the GC risk (...) associated with each OLGA stage. Consecutive patients (7436) underwent esophagogastroscopy (T-0), with mapped gastric biopsies, OLGA staging, and H. pylori status assessment. Patients with neoplastic lesion (invasive or non-invasive) at the index endoscopy (and/or within 12 months) were excluded. All patients were followed-up (T-1) by combining different sources of clinical/pathological information (Regional Registries of: (i) esophagogastroduodenoscopies; (ii) pathology reports; (iii) cancer, (iv

EvidenceUpdates2018

125. Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer

Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer 30286948 2018 10 05 1873-7560 2018 Oct 01 European urology Eur. Urol. Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. S0302-2838(18)30549-9 10.1016/j.eururo.2018.07.027 Systemic therapies, combined with local treatment for high-risk prostate cancer, are recommended (...) by the international guidelines for specific subgroups of patients; however, for many of the clinical scenarios, it remains a research field. To perform a systematic review, and describe current evidence and perspectives about the multimodal treatment of high-risk prostate cancer. We performed a systematic review of PubMED, Embase, Cochrane Library, European Society of Medical Oncology/American Society of Clinical Oncology Annual proceedings, and clinicalTrial.gov between January 2010 and February 2018 following

EvidenceUpdates2018

126. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study 30262187 2018 09 28 1474-5488 2018 Sep 21 The Lancet. Oncology Lancet Oncol. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. S1470-2045(18)30673-9 10.1016/S1470-2045(18)30673-9 Antibodies targeting the immune checkpoint molecules PD (...) -1 or PD-L1 have demonstrated clinical efficacy in patients with metastatic non-small-cell lung cancer (NSCLC). In this trial we investigated the efficacy and safety of avelumab, an anti-PD-L1 antibody, in patients with NSCLC who had already received platinum-based therapy. JAVELIN Lung 200 was a multicentre, open-label, randomised, phase 3 trial at 173 hospitals and cancer treatment centres in 31 countries. Eligible patients were aged 18 years or older and had stage IIIB or IV or recurrent NSCLC

EvidenceUpdates2018

127. Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial

Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial 30262574 2018 10 05 1399-3003 52 4 2018 Oct The European respiratory journal Eur. Respir. J. Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial. 1801220 10.1183/13993003.01220-2018 The anti-tumour and anti-metastatic properties of heparins have not been tested in patients with early stage cancer. Whether adjuvant (...) low molecular weight heparin (LMWH) tinzaparin impacts the survival of patients with resected non-small cell lung cancer (NSCLC) was investigated.Patients with completely resected stage I, II or IIIA NSCLC were randomly allocated to receive subcutaneous tinzaparin 100 IU·kg -1 once a day for 12 weeks or no treatment in addition to standard of care. The trial was open-label with blinded central adjudication of study outcomes. The primary outcome was overall survival.In 549 patients randomised to tinzaparin (n=269

EvidenceUpdates2018

128. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism

Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism 30240508 2018 10 25 1538-7836 2018 Sep 21 Journal of thrombosis and haemostasis : JTH J. Thromb. Haemost. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism. 10.1111/jth.14303 Essentials Bleeding risk by anticoagulant choice for cancer-associated venous thrombosis (CA-VTE) is unknown. 26 894 people with CA-VTE were (...) followed for bleeding in a claims database in the United States. Hospitalized bleeding risk was similar with direct acting oral anticoagulants vs. warfarin. Relative hospitalized bleeding risk varied by cancer type and anticoagulant choice. SUMMARY: Background Direct acting oral anticoagulants (DOACs) are associated with less bleeding than traditional venous thromboembolism (VTE) treatments in the general population but are little studied in cancer-associated VTE (CA-VTE). Objective To determine

EvidenceUpdates2018

129. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial

Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial 30199311 2018 09 10 1527-7755 2018 Sep 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4 (...) ) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial. JCO2018783183 10.1200/JCO.2018.78.3183 Purpose Cetuximab in combination with chemotherapy is a standard-of-care first-line treatment regimen for patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC); however, the efficacy of cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX) has never before been proven in a controlled and randomized phase III

EvidenceUpdates2018

130. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study 30217672 2018 10 10 1474-5488 19 10 2018 Oct The Lancet. Oncology Lancet Oncol. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study (...) . 1372-1384 S1470-2045(18)30481-9 10.1016/S1470-2045(18)30481-9 Adding pertuzumab to trastuzumab and chemotherapy improves survival in HER2-positive early breast cancer and metastatic breast cancer. We assessed the efficacy and safety of pertuzumab versus placebo in combination with trastuzumab and chemotherapy in first-line HER2-positive metastatic gastric or gastro-oesophageal junction cancer. JACOB was a double-blind, placebo-controlled, randomised, multicentre, phase 3 trial in patients aged 18

EvidenceUpdates2018

131. Evaluation of Interventions Intended to Increase Colorectal Cancer Screening Rates in the United States: A Systematic Review and Meta-analysis

Evaluation of Interventions Intended to Increase Colorectal Cancer Screening Rates in the United States: A Systematic Review and Meta-analysis 30326005 2018 10 19 2168-6114 2018 Oct 15 JAMA internal medicine JAMA Intern Med Evaluation of Interventions Intended to Increase Colorectal Cancer Screening Rates in the United States: A Systematic Review and Meta-analysis. 10.1001/jamainternmed.2018.4637 Colorectal cancer screening (CRC) is recommended by all major US medical organizations but remains (...) underused. To identify interventions associated with increasing CRC screening rates and their effect sizes. PubMed, Cumulative Index to Nursing and Allied Health Literature, the Cochrane Library, and ClinicalTrials.gov were searched from January 1, 1996, to August 31, 2017. Key search terms included colorectal cancer and screening. Randomized clinical trials of US-based interventions in clinical settings designed to improve CRC screening test completion in average-risk adults. At least 2 investigators

EvidenceUpdates2018

132. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems

In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems 30268859 2018 11 05 1879-2472 171 2018 Sep 19 Thrombosis research Thromb. Res. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care (...) systems. 97-102 S0049-3848(18)30534-6 10.1016/j.thromres.2018.09.050 Unprovoked venous thromboembolism (VTE) may be the first manifestation of an undiagnosed cancer. We assessed the cost-effectiveness of 18 F-Fluorodesoxyglucose Positron Emission/Computed Tomography (FDG PET/CT) plus limited screening and limited screening strategies in patients with unprovoked VTE from the perspectives of the Ontario (Canada) and French health care systems. We conducted a cost-effectiveness analysis based

EvidenceUpdates2018

133. First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Tr

First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Tr 30106636 2018 09 26 1527-7755 36 28 2018 Oct 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab (...) , in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. 2826-2835 10.1200/JCO.2017.76.7863 To assess pertuzumab plus trastuzumab and an aromatase inhibitor (AI) in patients with human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive metastatic/locally advanced breast cancer (MBC/LABC). The PERTAIN trial (NCT01491737) is an ongoing randomized, open

EvidenceUpdates2018

134. Atezolizumab (non-small cell lung cancer) ? Benefit assessment according to §35a Social Code Book V

Atezolizumab (non-small cell lung cancer) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Atezolizumab (nicht kleinzelliges Lungenkarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 December 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A17-50 Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-50 Version 1.0 Atezolizumab (non-small cell lung cancer) 27 December 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V Commissioning agency

Institute for Quality and Efficiency in Healthcare (IQWiG)2018

135. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer 30153097 2018 08 28 1527-7755 2018 Aug 28 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell (...) Lung Cancer. JCO2018783118 10.1200/JCO.2018.78.3118 Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated advanced non-small-cell lung cancer from the phase III FLAURA study. Patients and Methods Patients (N = 556) were randomly assigned to osimertinib or standard EGFR-TKIs (gefitinib or erlotinib); brain scans were not mandated unless clinically indicated. Patients

EvidenceUpdates2018

136. Guideline for the Management of Clostridium Difficile Infection in Children and Adolescents With Cancer and Pediatric Hematopoietic Stem-Cell Transplantation Recipients

Guideline for the Management of Clostridium Difficile Infection in Children and Adolescents With Cancer and Pediatric Hematopoietic Stem-Cell Transplantation Recipients 30216124 2018 11 14 1527-7755 2018 Sep 14 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Guideline for the Management of Clostridium Difficile Infection in Children and Adolescents With Cancer and Pediatric Hematopoietic Stem-Cell Transplantation Recipients (...) . JCO1800407 10.1200/JCO.18.00407 Purpose The aim of this work was to develop a clinical practice guideline for the prevention and treatment of Clostridium difficile infection (CDI) in children and adolescents with cancer and pediatric hematopoietic stem-cell transplantation (HSCT) patients. Methods An international multidisciplinary panel of experts in pediatric oncology and infectious diseases with patient advocate representation was convened. We performed systematic reviews of randomized controlled

EvidenceUpdates2018

137. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial 30196031 2018 10 10 1474-5488 19 10 2018 Oct The Lancet. Oncology Lancet Oncol. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. 1385-1393 S1470-2045(18)30380-2 (...) 10.1016/S1470-2045(18)30380-2 We previously reported the 5-year results of the phase 3 IBCSG 23-01 trial comparing disease-free survival in patients with breast cancer with one or more micrometastatic (≤2 mm) sentinel nodes randomly assigned to either axillary dissection or no axillary dissection. The results showed no difference in disease-free survival between the groups and showed non-inferiority of no axillary dissection relative to axillary dissection. The current analysis presents the results

EvidenceUpdates2018

138. Disease-free Survival and Local Recurrence After Laparoscopic-assisted Resection or Open Resection for Rectal Cancer: The Australasian Laparoscopic Cancer of the Rectum Randomized Clinical Trial

Disease-free Survival and Local Recurrence After Laparoscopic-assisted Resection or Open Resection for Rectal Cancer: The Australasian Laparoscopic Cancer of the Rectum Randomized Clinical Trial 30247332 2018 09 24 1528-1140 2018 Sep 20 Annals of surgery Ann. Surg. Disease-free Survival and Local Recurrence After Laparoscopic-assisted Resection or Open Resection for Rectal Cancer: The Australasian Laparoscopic Cancer of the Rectum Randomized Clinical Trial. 10.1097/SLA.0000000000003021 The aim (...) of the study was to determine the efficacy of laparoscopic rectal resection (Lap) versus open laparotomy and rectal resection (Open) for rectal cancer on locoregional recurrence (LRR) and disease-free survival (DFS) at 2 years. Although a Lap approach to colon cancer surgery may offer similar oncological outcomes to Open with potentially less morbidity, this remains to be clearly established for the treatment of rectal cancer. A randomized, multicenter noninferiority phase 3 trial of 475 patients with T1

EvidenceUpdates2018

139. Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis

Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis 30196195 2018 10 30 1879-2472 170 2018 10 Thrombosis research Thromb. Res. Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis. 175-180 S0049-3848(18)30483-3 10.1016/j.thromres.2018.08.023 Low-molecular-weight heparins (LMWHs) are the recommended treatment for cancer-associated venous thrombosis (CAT). Recent (...) and Cardiovascular Medicine - Stroke Unit, University of Perugia, Italy. eng Journal Article 2018 09 01 United States Thromb Res 0326377 0049-3848 Anticoagulants Cancer Embolism and thrombosis Meta-analysis Review 2018 06 28 2018 08 14 2018 08 31 2018 9 10 6 0 2018 9 10 6 0 2018 9 10 6 0 ppublish 30196195 S0049-3848(18)30483-3 10.1016/j.thromres.2018.08.023

EvidenceUpdates2018

140. Motivational interviewing added to oncology rehabilitation did not improve moderate-intensity physical activity in cancer survivors: a randomised trial

Motivational interviewing added to oncology rehabilitation did not improve moderate-intensity physical activity in cancer survivors: a randomised trial 30217412 2018 09 30 1836-9561 64 4 2018 Oct Journal of physiotherapy J Physiother Motivational interviewing added to oncology rehabilitation did not improve moderate-intensity physical activity in cancer survivors: a randomised trial. 255-263 S1836-9553(18)30114-0 10.1016/j.jphys.2018.08.003 Does adding weekly, physiotherapist-delivered (...) motivational interviewing to outpatient oncology rehabilitation for cancer survivors increase physical activity levels and improve physical and psychosocial outcomes that are typically impaired in this cohort? Randomised controlled trial with blinded outcome assessment, concealed allocation and intention-to-treat analysis. A heterogeneous sample of 46 cancer survivors (n=29 female; mean age 59 years) participating in a public outpatient oncology rehabilitation program. Participants were randomly allocated

EvidenceUpdates2018